Videos

David O'Malley, MD, looks at the preclinical signals of the novel MUC16 antibody ubamatamab, which showed promising results for patients with recurrent ovarian cancer.

Frederick Marme, MD, discusses new results from the TROPICS-02 study of sacituzumab govitecan for the treatment of patients with hormone receptor-positive, HER2-negative metastatic breast cancer.

Moshe Ornstein, MD, MA, continues his discussion of I/O-TKI combination regimens by presenting data from the CheckMate 9ER trial.

Moshe Ornstein, MD, MA, shares data from the KEYNOTE-426 clinical trial that set a new standard of care for treatment-naïve metastatic clear cell RCC.

Naveen Pemmaraju, MD discusses the long-term results of the STML-401-0114 trial that demonstrated the benefits of tagraxofusp-ezrs as a monotherapy for patients with blastic plasmacytoid dendritic cell neoplasms.

Matthew P. Goetz, MD, discusses recent data on estrogen receptor mutations in patients with breast cancer.

Isabelle Ray-Coquard, MD, discusses the final overall survival results from the phase 3 PAOLA-1/ENGOT-ov25 trial.

Gene G. Finley, MD, explains a questions lingering on the benefit of immunotherapy in patients with small call lung cancer.

Panelists identify second-line treatment options they would consider in advanced clear cell RCC if a patient progresses following first-line therapy.

Expert hematologist/oncologists consider the potential role for adjuvant immunotherapy in patients with advanced clear cell renal cell carcinoma.

Nizar Tannir, MD, presents the case of a 57-year-old patient with intermediate-risk advanced clear cell RCC, and Scott Tykodi, MD, PhD, presents data from the CheckMate 214 trial.

Experts explain the treatment goals for patients with MDS, and discusses the role of molecular testing in patients with MDS.

Dr Eytan M Stein breaks down how patients with MDS are risk-stratified, and how the clinical outcomes differ between risk groups.

Jean Bourhis, MD, discusses results from the phase 2 study of xevinapant plus chemoradiation vs placebo and chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck.

Key opinion leaders discuss the options for patients with advanced clear cell RCC who have higher-risk metastatic disease.

Paul G. Richardson, MD, discusses what is expected and exciting for the future of multiple myeloma research.

Salman Fazal, MD, explains how to lower the risk of graft-versus-host disease in patients who undergo allogeneic stem cell transplant.

Cary Gross, MD, discusses the background of his research on patients with lung cancer and Medicaid.

Naval G. Daver, MD, discusses the latest research on magrolimab, a CD47 monoclonal antibody, for patients with acute myeloid leukemia and myelodysplastic syndrome.

Melissa M. Hardesty discusses the key takeaways of the phase 2 OVARIO study of a PARP inhibitor plus a VEGF inhibitor in women with advanced ovarian cancer as well as research still needs to examine in this space.

Ian W. Flinn, MD, PhD, discusses what factors go into his decision to use polatuzumab plus bendamustine and rituximab in certain patients with relapsed/refractory diffuse large B-cell lymphoma.

Srdan Verstovsek, MD, PhD, highlights what future research in myeloproliferative neoplasms looks to examine.

Daniel J George, MD, shares his advice for community oncologists and discusses unmet needs when treating patients with advanced renal cell carcinoma.

Dr Daniel J George talks about the quality-of-life outcomes from the CHECKMATE 9ER and how different metastatic scenarios might affect treatment selection.

Dr Daniel J George reviews long term follow up data from the CHECKMATE 9ER and the implications of the data in the treatment paradigm for patients with advanced renal cell carcinoma.

Dr Daniel J George reviews long term follow up data from the CHECKMATE 9ER and the implications of the data in the treatment paradigm for patients with advanced renal cell carcinoma.

An expert oncologist explains how to calculate a patient’s risk status and provides an overview of front-line treatment options for patients with advanced renal cell carcinoma and discusses which factors are considered when choosing appropriate treatment.

Daniel J. George, MD, describes the case of a 68-year-old woman with advanced renal cell carcinoma.

Focused discussion on the selection of first-line therapy for advanced clear cell renal cell carcinoma based on sites of metastasis.

Expert panelists consider the importance of quality of life when selecting first-line treatment regimens for patients with advanced clear cell renal cell carcinoma.